Open AccessPB1827 LENALIDOMIDE AND RITUXIMAB COMBINED WITH CEP CHEMOTHERAPY (R 2 CEP) FOR PATIENTS WITH RELAPSED B‐CELL LYMPHOMA.
Author(s) -
Guidez S.,
Gruchet C.,
Tomowiak C.,
Bobin A.,
Debiais C.,
Machet A.,
Delwail V.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000565812.69164.2c
Subject(s) - medicine , rituximab , lenalidomide , follicular lymphoma , etoposide , regimen , neutropenia , gastroenterology , lymphoma , chemotherapy , prednisone , febrile neutropenia , cyclophosphamide , oncology , surgery , multiple myeloma
Background: Patients with relapse or refractory (R/R) B‐cell Non Hodgkin Lymphoma (B‐NHL), especially DLBCL, have a poor prognostic mainly because of the difficulty of effective treatment. In patients relapsed after intensive chemotherapy or unfit patients, the treatment are not very effective and access to a clinical trial is not always possible. Aims: Based on the results of the combination of lenalidomide and rituximab in B‐cell lymphoma, we combined this regimen with conventional CEP chemotherapy (cyclophosphamide, etoposide, and prednisone) in patients with R/R B‐NHL most often DLCL. Methods: Thirteen patients were treated by R 2 CEP regimen from June 2017. The median age was 82 years (58‐92). Eleven patients presented a DLBCL including 1 transformed follicular, 1 MCL and 1 follicular lymphoma. Patients had received an average of 2 prior lines of treatment (1‐4) and presented for 11 of them an advanced stage (III‐IV) at relapse. Patients were treated by R 2 CEP association with: rituximab 375 mg/m 2 D1, cyclophosphamide 750 mg/m 2 D1, etoposide 100 mg/m 2 D1, prednisone 50 mg/m 2 D1 to D5 and lenalidomide 10 mg by day D1 to D14, 21‐days cycles for 6 cycles of treatment. Results: Five patients are still being treated. Two patients stopped the treatment for progression. Only one patient experienced an episode of febrile neutropenia. Seven patients achieved complete response. With a median follow up of 4.5 months (0.5‐13.2), one patient died of lymphoma progression. Summary/Conclusion: In patients with R/R DLBCL lymphoma, the combination with lenalidomide‐rituximab and CEP chemotherapy seems to be a well tolerated therapeutic option and our preliminary results seems to show an efficiency of this scheme. The results will be updated for the congress.